Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestors.amgen.com
Amgen Inc. News Releases
Get the latest updates from Amgen Inc. News Releases directly as they happen.
Follow now 184 followers
Latest posts
Last updated 4 days ago
REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C
4 days ago
THOUSAND OAKS, Calif. , Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...
AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
23 days ago
THOUSAND OAKS, Calif. , Aug. 5, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...
AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND
27 days ago
THOUSAND OAKS, Calif. , Aug. 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...
AMGEN ANNOUNCES WEBCAST OF 2025 SECOND QUARTER FINANCIAL RESULTS
28 days ago
THOUSAND OAKS, Calif. , July 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER
about 2 months ago
At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in...
RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
2 months ago
MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up...
AMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
2 months ago
MariTide is the First Monthly or Less Frequently Dosed Peptide-Antibody Conjugate Being...
AMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY
3 months ago
The Making of a Heart Attack Educates Viewers About High LDL-C— a...
AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
3 months ago
THOUSAND OAKS, Calif. , June 5, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN)...
IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS
3 months ago
Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy Late-Breaking Data Presented...
AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
3 months ago
THOUSAND OAKS, Calif. , May 30, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will...
AMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE
3 months ago
THOUSAND OAKS, Calif. , May 16, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will...